Literature DB >> 18844711

Medical treatment of hirsutism.

Ulrike Blume-Peytavi1, Susanne Hahn.   

Abstract

Hirsutism is usually the result of an underlying adrenal, ovarian, or central endocrine abnormality mainly due to polycystic ovary syndrome but may also be idiopathic or drug induced. The aim of medical treatment of hirsutism is to rectify any causal hormonal balance, slow down or stop excessive hair growth, and improve the aesthetic appearance of hirsutism, thereby positively affecting the patient's quality of life. Today, for the majority of women, a monotherapy with oral contraceptives that have antiandrogenic activity is recommended as a first-line treatment for hirsutism. Combining an oral contraceptive pill with an antiandrogen is recommended if clinical improvement of hirsutism is insufficient after 6-9 months' monotherapy. In women who present with hirsutism, hyperandrogenism, and insulin resistance, insulin sensitizers are effective for the hirsutism as well as the hyperinsulinemia, hyperandrogenism, and infertility but there is no convincing evidence that they are effective for hirsutism alone. Topical eflornithine is a medical therapy that can be a useful adjuvant for hirsutism when used in conjunction with systemic medications or with laser/photoepilation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18844711     DOI: 10.1111/j.1529-8019.2008.00215.x

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  10 in total

1.  Hirsutism in a female adolescent induced by long-acting injectable risperidone: a case report.

Authors:  Ankit Patel; Naaz Malek; Fasiha Haq; Lauren Turnbow; Shakeel Raza
Journal:  Prim Care Companion CNS Disord       Date:  2013

2.  Allicin, a Potent New Ornithine Decarboxylase Inhibitor in Neuroblastoma Cells.

Authors:  Chad R Schultz; Martin C H Gruhlke; Alan J Slusarenko; André S Bachmann
Journal:  J Nat Prod       Date:  2020-08-12       Impact factor: 4.803

3.  Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma.

Authors:  Chad R Schultz; Matthew A Swanson; Thomas C Dowling; André S Bachmann
Journal:  Cancer Chemother Pharmacol       Date:  2021-06-15       Impact factor: 3.333

4.  Evaluation of the effect of formic acid and sodium formate on hair reduction in rat.

Authors:  Mahnaz Banihashemi; Abolfazl Khajavi Rad; Seyed Abbas Tabatabaee Yazdi; Hasan Rakhshande; Vahid Mashayekhi Ghoyonlo; Zahra Zabihi; Hadis Yousefzadeh
Journal:  Clin Cosmet Investig Dermatol       Date:  2011-06-02

5.  Congenital adrenal hyperplasia.

Authors:  Cleo Dessinioti; Andreas Katsambas
Journal:  Dermatoendocrinol       Date:  2009-03-01

6.  A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma.

Authors:  Giselle L Saulnier Sholler; Eugene W Gerner; Genevieve Bergendahl; Robert B MacArthur; Alyssa VanderWerff; Takamaru Ashikaga; Jeffrey P Bond; William Ferguson; William Roberts; Randal K Wada; Don Eslin; Jacqueline M Kraveka; Joel Kaplan; Deanna Mitchell; Nehal S Parikh; Kathleen Neville; Leonard Sender; Timothy Higgins; Masao Kawakita; Kyoko Hiramatsu; Shun-Suke Moriya; André S Bachmann
Journal:  PLoS One       Date:  2015-05-27       Impact factor: 3.240

Review 7.  Dermatosis associated with menopause.

Authors:  Pragya A Nair
Journal:  J Midlife Health       Date:  2014-10

8.  A Novel Effect of Acyclovir on Hair Growth in BALB/c Mice: A Promising Future for Finding a New Topical Drug for the Treatment of Hirsutism.

Authors:  Soran Sameei; Hamid Soraya; Morteza Ghasemnejad-Berenji
Journal:  Clin Cosmet Investig Dermatol       Date:  2020-04-24

9.  Dihydrotestosterone Regulates Hair Growth Through the Wnt/β-Catenin Pathway in C57BL/6 Mice and In Vitro Organ Culture.

Authors:  Xianyan Chen; Ben Liu; Ying Li; Le Han; Xin Tang; Wenjia Deng; Wei Lai; Miaojian Wan
Journal:  Front Pharmacol       Date:  2020-01-23       Impact factor: 5.810

10.  Application of Hantzsch reaction for sensitive determination of eflornithine in cream, plasma and urine samples.

Authors:  Albandary Almahri; Mohamed A Abdel-Lateef
Journal:  R Soc Open Sci       Date:  2021-05-12       Impact factor: 2.963

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.